

## Scientific Program

### BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00  
Thursday, October 6

Chair Persons: T. Regad, J. Kwon, H. Kijima

309. Cellular pathways regulating the function of MTSS1 in HER2-positive breast cancer. D.G. Powe, M.E. Buczek, C. Johnson, A. Schneider, J. Vadakekolathu, I.O. Ellis, A.G. Pockley, R.C. Rees, G.R. Ball, **T. Regad** (Nottingham, UK) (25')
235. The role of BAP1 and INO80 in genome stability and cancer. S.-A. Lee, H.-S. Lee, H. Seo, S.-J. Kwon, D. Jeong, **J. Kwon** (Seoul, Republic of Korea) (25')
269. The bHLH transcription factor DEC plays an important role in epithelial-mesenchymal transition (EMT). **H. Kijima**, Y. Wu, T. Yoshizawa, H. Seino, S. Goto, T. Haga, S. Morohashi (Hirosaki, Japan) (25')
314. Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damage. C. Pantelidou, Y.K.S. Man, L. Coughlan, J. Marshall, H. Kocher, **G. Haldén** (London, UK) (25')
412. Automated cell picking and single-cell digital PCR focusing on mitochondrial transfer. **D. Svec** (Gothenburg, Sweden; Vestec u Prahy, Czech Republic) (20')

### EXPERIMENTAL THERAPEUTICS

Room A, 11:30-13:00  
Thursday, October 6

Chair Persons: M. Danilenko, J.A. McCubrey, H.M. Said

281. Vitamin D-based differentiation therapy for acute myeloid leukemia: Novel aspects. M. Nachliely, A. Trachtenberg, E. Sharony, A. Kutner, Y. Sharoni, G.P. Studzinski, **M. Danilenko** (Beer-Sheva, Israel; Newark, NJ, USA) (25')
133. Role of neutrophil gelatinase-associated lipocalin (NGAL) in therapeutic sensitivity. **J.A. McCubrey**, S. Abrams, W. Chappell, T.L. Fitzgerald, K. Lertpiriyapong, A.M. Martelli, L. Cocco, M. Cervello, G. Montalto, S. Candido, M. Libra, L.S. Steelman (Bologna; Catania, Italy) (25')
134. Effects of p53 on pancreatic cancer sensitivity to various therapeutics. **L.S. Steelman**, S.L. Abrams, T.L. Fitzgerald, K. Lertpiriyapong, L. Cocco, A.M. Martelli, M. Cervello, G. Montalto, M. Libra, M. La Hair, R.A. Franklin, J.A. McCubrey (Bologna; Palermo; Catania, Italy) (15')
407. Molecular regulation of hypoxia induced genes related to human cancer. **H.M. Said**, D. Harmanci, A. Kocak, C. Ural, G. Gül, B. Acikgoz, F.D. Ince, Y. Soysal, C. Hagemann (Izmir, Turkey; Würzburg, Germany) (25')

## CANCER THERAPEUTICS

Room A, 16:00-17:30  
Thursday, October 6

Chair Persons: S.N. Karagiannis, V. Ganapathy

224. IgE immunotherapy for cancer: Revealing novel mechanisms to redirect host effector cells against solid tumours. **S.N. Karagiannis** (London, UK) (30')
306. Therapeutic potential of Carbidopa as an anticancer drug. **V. Ganapathy** (Lubbock, TX, USA) (30')
311. Modulation of alternative splicing as a novel therapeutic avenue in cancer. E. Star, A. Mavrou, L. Li, **S. Oltean** (Bristol, UK) (30')

## microRNAs

Room A, 18:00-19:30  
Thursday, October 6

Chair Persons: G. Glady, S.S. Signorelli

146. Epigenetic regulation of EMT using the regulatory potential of microRNAs. **G. Glady** (Colmar, France) (30')
373. Biomarkers on pathophysiology of chronic ischemia. Potential role of mRNAs and oxidative stress in peripheral arterial disease. **S.S. Signorelli**, V. Fiore, L. Vanella, G. Li Volti (Catania, Italy) (30')
361. A liquid biopsy model: Circulating miRNA levels in mice bearing colorectal carcinoma tumor xenografts. **A. Finotti**, E. Tremante, J. Gasparello, E. Fabbri, N. Bianchi, M. Allegretti, P. Giacomini, R. Gambari (Rome, Italy) (15')
371. Computational analysis of microRNA expression in bladder cancer. **L. Falzone**, S. Candido, A. Scalisi, M. Libra (Catania, Italy) (15')

## IMMUNOLOGY/HYPOXIA

Room B, 09:00-11:00  
Thursday, October 6

Chair Persons: M.Z. Ratajczak, T. Grundström, D.W. Felsher

106. The novel role of the activation of complement cascade in the pathogenesis of hematopoietic malignancies and the modulatory effect of heme oxygenase-1 (HO-1). **M.Z. Ratajczak** (Louisville, KY, USA; Szczecin, Poland) (25')
253. Regulation of diversification and affinity maturation of antibodies. **T. Grundström**, J. Hauser, C. Grundström, A. Kumar, A. Priya, R. Kumar (Umeå, Sweden) (25')
413. The MYC oncogene regulates the immune response. **D.W. Felsher** (Stanford, CA, USA) (20')
333. The role of Dicer in carcinogenesis. **K.-F. Tang** (Wenzhou, P.R. China) (20')
145. BHLH transcription factor DEC1 promotes hypoxia-induced EMT of HepG2 cells. **K. Murakami**, Y. Wu, Y. Aoki, H. Seino, S. Morohashi, T. Imaizumi, H. Kijima (Hirosaki, Japan) (15')
148. Post-translational regulation of glutamine metabolism by acetylases and deacetylases in breast cancer cells under hypoxic conditions. A.C.S. Peng, L.C. Onn, E. Chitra, F.A. Davamani, S. Ambu, C. Demonacos, **R. Rajendran** (Kuala Lumpur, Malaysia; Manchester, UK) (15')

## CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:20  
Thursday, October 6

Chair Persons: J. Guo, M. Linxweiler, G. Gillet

194. Translational research in pancreatic cancer: The experience of Peking Union Medical College Hospital. **J. Guo** (Beijing, P.R. China) (20')
401. Role of apoptosis regulators of the Bcl-2 family in the control of cell motility during development and tumor progression. **G. Gillet** (Lyon, France) (30')
143. Trifluoperazine as a potential antimetastatic agent in human cancer - From molecular biology to clinical application. **M. Linxweiler**, F. Bochen, R. Zimmermann, M. Greiner, C. Körbel, M.D. Menger, B. Schick (Homburg, Germany) (15')
101. CD73: A therapeutic target for pancreatic neuroendocrine tumor stem cells. **E. Katsuta**, S. Tanaka, K. Mogushi, S. Shimada, Y. Akiyama, A. Aihara, S. Matsumura, Y. Mitsunori, D. Ban, T. Ochiai, A. Kudo, H. Fukamachi, H. Tanaka, K. Nakayama, S. Arii, M. Tanabe (Tokyo, Japan) (15')
136. A novel thyroid function parameter predicts opposite therapeutic outcomes in advanced hepatoma treated by chemotherapy or sorafenib. **C.-T. Yeh**, K.-H. Lin, Y.-H. Huang, K.-H. Liang, C.-C. Lin, C.-F. Hung (Taoyuan; Taipei, Taiwan, R.O.C.) (15')
250. Role of anoctamin in glaucoma and cancer. **J. Banerjee**, C.-T. Leung, A. Li, K. Peterson-Yantorno, H. Ouyang, W.D. Stamer, M.M. Civan (Philadelphia, PA; Durham, NC, USA; Guangzhou, P.R. China) (15')

## METASTASIS/PROGRESSION

Room B, 16:00-17:30  
Thursday, October 6

Chair Persons: G. Neufeld, C. Sato

142. Modulation of tumor lymphangiogenesis and tumor progression by Semaphorin-3C. Y. Mumblat, O. Kessler, N. Ilan, **G. Neufeld** (Haifa, Israel) (30')
270. Observation of tissues in solution using atmospheric SEM: Applicability for quick intraoperative cancer diagnosis. **C. Sato**, N. Memtily, T. Ebihara, T. Okada, M. Kawata, M. Sato, T. Yamazawa (Ibaraki, Japan) (30')
125. Host JDP2 expression in the bone marrow contributes to metastatic spread. Y. Barbarov, Y. Shaked, **A. Aronheim** (Haifa, Israel) (15')
144. Lymphangiogenesis, hemangiogenesis and lymph node metastasis in squamous cell carcinoma of the cervix. **R. Huang**, T.G. Simonsen, L.M.K. Andersen, K. Galappathi, C. Ellingsen, C.S. Wegner, A. Hauge, J.-V. Gaustad, E.K. Rofstad (Oslo, Norway) (15')

## APOPTOSIS/HYPOXIA

Room B, 18:00-19:30  
Thursday, October 6

Chair Persons: N.A.P. Franken, B. Ozpolat

118. Inducing apoptosis in cervical carcinoma by targeting HPV-E6 with hyperthermia. A.L. Oei, C.M. van Leeuwen, R. ten Cate, H.M. Rodermond, M.R. Buist, L.J.A. Stalpers, J. Crezee, H.P. Kok, J.P. Medema, **N.A.P. Franken** (Amsterdam, The Netherlands) (30')
128. Development of novel targeted therapies for triple negative breast cancer: Targeting EF2-kinase. **B. Ozpolat** (Houston, TX, USA) (30')
141. Hypoxia promotes chemotherapy resistance by regulating SKA1 in human osteosarcoma. **Q. Ma**, Y. Zhang, T. Liu, K. Jiang, Y. Wen, Q. Fan, X. Qiu (Xi'an, P.R. China) (15')
400. Expression of human beta-defensin 1 in pterygium patient. **A.A. Sa'adatu**, M.I. Muhammad, N. Omar, S.W. Tan (Serdang, Malaysia) (15')

## EXPERIMENTAL CARCINOGENESIS

Room C, 09:00-11:00  
Thursday, October 6

Chair Persons: P. Yang, S.R. Inamdar

199. Dietary sugar induces tumorigenesis in mammary gland partially through 12 lipoxygenase pathway. Y. Jiang, Y. Pan, P.R. Rhea, M. Gagea-Iurascu, L. Cohen, **P. Yang** (Houston, TX, USA) (30')
271. Tumour suppressing effect of *Sclerotium rolfsii* lectin and its pharmacokinetics using *in vivo* models. **S.R. Inamdar**, S. Anupama, P. Laha, K. Pathak, S. Bane, A. Ingle, V. Gota, R.D. Kalraiya, J.M. Rhodes, L. Yu, B.M. Swamy (Dharwad; Navi Mumbai, India; Liverpool, UK) (30')
298. Heme: A key oncometabolite promoting lung tumorigenesis. M.M. Alam, S. Sohoni, S.P. Kalainayakan, C. Vidal, P. Ghosh, K.E. Fitzgerald, **L. Zhang** (Richardson, TX, USA) (30')
132. Synthesis and antitumor activity of *ent*-kaurane diterpenoid derivatives. **D. Li**, S. Xu, Z. Li, J. Xu, H. Hua (Shenyang; Nanjing, P.R. China) (30')

## MOLECULAR ONCOLOGY/CLINICAL ONCOLOGY

Room C, 11:30-13:10  
Thursday, October 6

Chair Persons: X.-N. Li, H. Okamura

102. Patient-derived orthotopic xenograft (PDOX) mouse models of malignant brain tumors for preclinical drug screening. L. Qi, M. Kogiso, Y. Du, H.B. Lindsay, H. Zhang, S. Zhao, F.K. Braun, Q. Shu, X. Zhao, Z. Liu, Y. Huang, L. Perlaky, J. Su, P. Baxter, A. Adesina, D. Parsons, **X.-N. Li** (Houston, TX, USA) (20')
375. Cancer immunotherapy targeting innate immunity. Z. Ma, W. Li, M. Hata, Y. El-Darawish, K. Yamanishi, H. Yamanishi, Y. Tanaka, **H. Okamura** (Hyogo; Osaka; Nagasaki, Japan) (20')
129. EphA2 targeted siRNA nanotherapeutics for ovarian cancer. **G. Lopez-Berestein** (Houston, TX, USA) (15')
312. Tumours induced by heavy particle radiotherapy: The first report of two cases, intracranial cavernoma and malar osteosarcoma. **A. Adachi**, A. Hara, K. Horiguchi, M. Kubota, T. Matsutani, M. Kambe, A. Hasegawa, T. Inaniwa, T. Hanazawa, Y. Okamoto, Y. Iwadata (Chiba; Anagawa, Japan) (15')
387. A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. **T.-T. Pan**, W. Wang, W.-D. Jia, G.-L. Xu (Hefei, P.R. China) (15')
335. HIF-1 $\alpha$ -ADAM10 induces hepatocellular carcinoma escape from NK cells by secreting soluble ULBP2. **M. Huang**, W. Jia, W. Ren, J. Ma, Q. Huang, G. Xu (Hefei, P.R. China) (15')

## IMMUNOLOGY/MOLECULAR ONCOLOGY

Room C, 16:00-17:30  
Thursday, October 6

Chair Persons: D.J. Lee, F. Nicoletti

117. Molecular profiling of metastatic melanoma prior to the era of checkpoint blockade consistently points to immune pathways as an important indicator of survival. R.D. Lardone, **D.J. Lee** (Santa Monica, CA, USA) (30')
374. NO-hybridized protease inhibitors as novel drugs for the treatment of cancer and autoimmune diseases. **F. Nicoletti**, P. Fagone, S. Mammana, S. Basile, E. Cavalli, K. Mangano (Catania, Italy) (30')
267. Varied immune modulatory effects of reactive nitrogen oxide species in tumor associated myeloid cells. **V. Somasundaram**, D. Basudhar, L.A. Ridnour, R. Cheng, D.A. Wink (Frederick, MD, USA) (15')
310. Self-extracellular RNA as new alarm signal in innate immunity. **S. Fischer**, F. Noll, J. Behnke, A.-K. Elsemüller, K.T. Preissner (Giessen, Germany) (15')

## CHEMOTHERAPY/PHARMACOLOGY

Room C, 18:00-19:30  
Thursday, October 6

Chair Persons: T. Eckschlager, F. Buxant

326. Apoferritin loaded by cytostatics and its effect on cancer cells. T. Cerna, J. Hrabeta, Z. Heger, S. Dostalova, V. Adam, M. Stiborova, **T. Eckschlager** (Prague; Brno, Czech Republic) (30')
276. Pre-exposure of the MCF-7 breast cancer cell line to dexamethasone alters the cytotoxic effect of paclitaxel but not that of 5-Fluorouracil and epirubicin chemotherapy. **F. Buxant**, N. Kindt, J.-C. Noël, G. Laurent, S. Saussez (Brussels; Mons, Belgium) (20')
176. The analogue human cathelicidin antimicrobial peptide is a potential anticancer drug. **K. Kuroda**, T. Fukuda, H. Isogai, K. Okumura, M. Krstic-Demonacos, E. Isogai (Sendai; Morioka; Sapporo; Hokkaido, Japan; Salford, UK) (20')
137. Janus-type nucleosides: Design, synthesis and their primary application in cancer therapy. **Q. Chen**, Y. He, H. Zhao (Chengdu, P.R. China) (20')

## MOLECULAR MEDICINE/PHARMACOLOGY

Room D, 09:00-11:00  
Thursday, October 6

Chair Persons: Y. Liu, Y. Mizrahi Nebenzahl

195. Chromatin configuration and epigenetic regulation in oocytes and embryos. L. Qiao, L. Zhang, X. Wu, J. Xin, F. Kong, J. Xie, **Y. Liu** (Fuyang, P.R. China) (30')
275. New generation vaccines and novel therapies to combat *S. pneumonia*-inflicted diseases. **Y. Mizrahi Nebenzahl** (Beer Sheva, Israel) (30')
233. Anti-cancer and anti-microbial activities of ellagitannin oligomers from *Punica granatum*. **A. Ide**, K. Kuroda, M. Hayashi, K. Saito, T. Iwaya, N. Nishida, M. Kohno, H. Ito, E. Isogai (Sendai; Osaka; Okayama, Japan) (15')
232. UV-regulated long non-coding RNAs: Expression and activity. **E. Shaulian** (Jerusalem, Israel) (15')
149. Effects of trans-isoferulic acid and gallic acid on cardiac contractility: Is there a role for CaMKII? S. Currie, K.T.S. Qim, H.H. Mum, S.J. Campbell, G. MacKenzie, H. Salleh, D.K. Chellapan, **M. Candasamy** (Glasgow, UK; Kuala Lumpur, Malaysia) (15')
160. Emerging role of flavonoids in anticancer therapy. J.M. Han, D.Y. Sim, B. Kim, N. Jung, S. Lee, **H.J. Jung** (Asan-si, Republic of Korea) (15')

## MOLECULAR MEDICINE

Room D, 11:30-13:20  
Thursday, October 6

Chair Persons: G. Hong, C. Bernabeu

115. Total paeony glycoside has a biological effect on the promotion of steroid-induced osteonecrosis in femoral head healing. **G. Hong**, L. Chen, X. Chen, D. Chen, W. He (Guangzhou, P.R. China) (20')
198. An update on the role of membrane and soluble endoglin in vascular homeostasis. **C. Bernabeu** (Madrid, Spain) (15')
116. Novel association of sICAM-1 and sP-selectin with the ABO blood groups in a Chinese population. **W. Zhang**, Q. Xu, Y. Zhuang, Y. Chen (Jinan, P.R. China) (15')
226. Redox homeostasis in the maintenance of *Drosophila* germline and cyst stem cells. S.W.S. Tan, Q.Y. Lee, **G.H. Baeg** (Singapore, Republic of Singapore) (15')
389. Icaritin improves osteoporosis, inhibits the expression of PPAR $\gamma$ , C/EBP $\gamma$ , FABP4 mRNA, N1ICD, and jagged1 proteins and increases Notch2 mRNA in ovariectomized rats. H. Liu, **Y. Xiong**, H. Gao, S. Yin, J. Wang, G. Chen, C. Wang, L. Xiang, P. Wang, J. Fang, R. Zhang, X. Zhu, L. Yang (Guangzhou, P.R. China) (15')
404. A draft map of the telomerase spliceosome proteome. **Y. Wu**, Y. Zhang, H. Yang, Y. Yang, S. Yang (Chongqing, P.R. China) (15')
230. Versican and hyaluronan expression levels are indicative of benign soft tissue or metastatic sarcoma tumor fate. **P.A. Keire**, K. MacDonald, P. Vishnu, T.N. Wight (Seattle, WA, USA) (15')

## MOLECULAR MEDICINE

Room D, 16:00-17:30  
Thursday, October 6

Chair Persons: P.E. Nielsen, T. Nakamura

261. Dystrophin splice switching PNAs for Duchenne muscular dystrophy treatment. **P.E. Nielsen**, C. Brolin (Copenhagen, Denmark) (30')
205. The p53-deficient tumor cells may recruit tumor-associated macrophages and enhance their expression of indoleamine 2, 3-dioxygenase in transgenic mice. **T. Nakamura** (Kurashiki, Japan) (30')
203. Induction of hepatic Bach1 mRNA in a rat model of acute liver injury. **T. Takahashi** (Okayama, Japan) (15')
209. The effect of feeding pregnant and lactating mice *Rhodiola kirilowii* extracts on some parameters of immune system of their progeny. **S. Lewicki**, R. Zdanowski, W. Stankiewicz, M. Krzyzowska, B.J. Bałan, E. Skopińska-Różewska (Warsaw, Poland) (15')

## MOLECULAR MEDICINE/SIGNALING

Room D, 18:00-19:30  
Thursday, October 6

Chair Persons: L.A. Stone, K. Yamanishi

246. Central ghrelin resistance: A newly discovered consequence of chronic stress, with implications for stress-associated mental illness. **L.A. Stone**, K.A. Goosens (Cambridge, MA, USA) (20')
272. Interleukin-18-deficient mice develop dysfunction of hippocampus resulting in depression-like behavior. **K. Yamanishi**, N. Doe, K. Ikubo, T. Hashimoto, M. Sumida, S. Kuwahara-Otani, S. Maeda, Y. Watanabe, W. Li, T. Hayakawa, H. Okamura, H. Yamanishi, H. Matsunaga (Nishinomiya; Kobe; Hirakata, Japan) (20')
258. TRPV4 and TRPV6 channels control proliferation, insulin expression and secretion in INS-1E beta cells. **M. Skrzypski**, N. Khajavi, S. Mergler, M. Billert, D. Szczepankiewicz, T. Wojciechowicz, K.W. Nowak, M.Z. Strowski (Poznań, Poland; Berlin, Germany) (20')
140. Survivin as a novel target of the Hedgehog signaling pathway effector Gli2 in human cancer. K. Vlčková, **J. Vachtenheim**, L. Ondrušová, J. Réda, P. Dunder, M. Zadinová (Prague, Czech Republic) (15')
227. The signaling pathway mediated by Sirt1 in tumor. **F. Yuan**, L. Liu (Beijing, P.R. China) (15')



## BIOMARKER DISCOVERY/CLINICAL ONCOLOGY

Room E, 09:00-11:00  
Thursday, October 6

Chair Persons: R. Kiss, N. Kentepozidis

119. How can we improve *in vitro* and *in vivo* preclinical screening of promising marine-derived anticancer compounds? **R. Kiss** (Brussels, Belgium) (30')
295. Recent advances in metastatic pancreatic cancer. **N. Kentepozidis** (Athens, Greece) (30')
123. Forensic identification of a fire carbonized body by STR genotyping. **R. Dumache**, C. Muresan, V. Ciocan, A. Enache (Timisoara, Romania) (15')
174. Characterization of long non-coding RNA-associated ceRNA network to reveal potential lncRNA biomarkers in human lung adenocarcinoma. **J. Sui**, Y. Zhang, C. Li, X. Shen, W. Yao, H. Peng, W. Hong, L. Yin, Y. Pu, G. Liang (Nanjing, P.R. China) (15')
304. The effect of WT1 on aggressiveness of triple negative breast cancer. R. Bissanum, R. Navakanitworakul, K. Lirdprapamongkol, **K. Kanokwiroon** (Hat Yai; Bangkok, Thailand) (15')
220. Methylation markers in colorectal cancer: Where are we now? **A. Khamas** (Bidiya, Oman) (15')

## MOLECULAR ONCOLOGY

Room E, 11:30-13:15  
Thursday, October 6

Chair Persons: M. Borgatti, L. Elnitski

358. SPR-based biosensor for non-invasive prenatal diagnosis of Y-chromosome. G. Breveglieri, L.C. Cosenza, P. Pellegatti, G. Guerra, F. Salvatori, E. D'Aversa, A. Finotti, R. Gambari, **M. Borgatti** (Ferrara, Italy) (15')
251. Assessing *ZNF154* hypermethylation from circulating tumor DNA in pan-cancer diagnostics. G. Margolin, H.M. Petrykowska, N. Jameel, D.W. Bell, A.C. Young, **L. Elnitski** (Rockville, MD; Bethesda, MD, USA) (15')
202. Rapamycin and fructose-1,6-bisphosphate reduce the HEPG2 cell proliferation via increase of free radicals and apoptosis. **E. Feller Gonçalves da Silva**, G.C. Krause, G.V. Haute, K.G. Lima, F.C. Mesquita, L. Pedrazza, B. Souza Basso, A.C. Velasquez, J.R. De Oliveira, F.B. Nunes (Porto Alegre, Brazil) (15')
300. Tumorigenicity and expression of the core stem cell markers in rhabdomyosarcoma cells. **R. Veselska**, A. Nunukova, J. Skoda, T. Loja, I. Zambo, J. Neradil, M. Hermanova, A. Hampl, J. Sterba (Brno, Czech Republic) (15')
228. Effects of 17-AAG on the cell cycle and apoptosis of HCT-15 and HCT-16 cells and the associated mechanisms. **X. Zhao**, J. Wang, L. Xiao, Q. Xu, E. Zhao, X. Zheng, H. Zheng, S. Zhao, S. Ding (Chengde; Jinzhou; P.R. China) (15')
188. Effects of embedding medicine in acupoints and electro-acupuncture on expression of Fas and HSP70 in hippocampus of rat with focal cerebral ischemia reperfusion. S. Gao, **B. Wu** (Wuhan; Beijing, P.R. China) (15')
189. The effect of pulsed radiofrequency on dorsal root ganglion on the met-enkephalin and substance P levels in the spinal cord in spinal nerve injury rats. **B. Wu** (Beijing, P.R. China) (15')

## EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00  
Friday, October 7

Chair Persons: S.M. Post, J.-P. Gillet

293. Identification of novel regulators and therapeutic targets in hematologic malignancies. **S.M. Post**, M. Gallardo, M.J. Hornbaker, X. Zhang, C. Bueso-Ramos, J. Parker-Thornburg, P. Hu, I. Rapado, A. Quintas-Cardama, S.M. Kornblau, J. Martinez-Lopez (Houston, TX, USA; Madrid, Spain) (30')
114. The multifaceted ABCB5 transporter: Spotlight on its role in tumorigenesis. **J.-P. Gillet**, G. Sana, J.P. Madigan, J.J. Gartner, C.-H. Lin, M. Fourrez, S. Shukla, S.V. Ambudkar, R.M. Rutledge, D. Xia, S.A. Rosenberg, M.M. Gottesman, Y. Samuels (Namur, Belgium; Bethesda, MD, USA; St. Louis, Missouri, USA; Rehovot, Israel) (30')
107. Heart peptide hormones: Adjunct and primary treatments of cancer. **D.L. Vesely** (Tampa, FL, USA) (30')
155. Potential clinical use of liquid biopsy in colorectal cancer patients. **G. Norcic**, P. Cerkovnik, V. Stegel, S. Novakovic (Ljubljana, Slovenia) (30')

## MOLECULAR ONCOLOGY

Room A, 11:30-13:00  
Friday, October 7

Chair Persons: S. Bonni, E. Agostinelli

157. Sumoylation pathways regulating EMT in mammary epithelial cells and tumor metastasis. **S. Bonni** (Calgary, Canada) (30')
158. Proteomic studies of the mechanism of cytotoxicity, induced by polyamine metabolites in human cancer cells, as a new approach to cancer therapy. **E. Agostinelli**, C. Barrero, S. Ohkubo, S. Grancara, A. Toninello, S. Merali (Rome; Padova Italy) (30')
337. Role of RASSF1A methylation in human malignancies. **G. Malpeli** (Verona, Italy) (30')

## INFLAMMATION/TUMOR BIOLOGY

Room A, 16:00-17:30  
Friday, October 7

Chair Persons: M. Shibata, V. Righi

120. Inflammation-related immune suppression in patients with cancer. **M. Shibata**, K. Gonda, T. Nakajima, T. Shimura, K. Kono, S. Takenoshita (Saitam; Fukushima, Japan) (30')
356. NMR contribution to the comprehension of metabolic disorders in inflammatory and neoplastic hyper-proliferative disease. **V. Righi**, A. Mucci, N. Fazio, C. Magnoni (Bologna; Modena, Italy) (30')
197. The epigenetic enzyme Naa40 controls apoptosis in colorectal cancer cells. D. Pavlou, C. Demetriadou, **A. Kirmizis** (Nicosia, Cyprus) (30')

## THERAPEUTICS/TUMOR MICROENVIRONMENT

Room A, 18:00-19:30  
Friday, October 7

Chair Persons: L.F. Gibson, L. Vannucci

248. The early tumor microenvironment: Stroma and immunity. **L. Vannucci**, F. Caja, D. Stakheev, J. Krizan, O. Chernyavskiy, P. Makovicky, R. Sedlacek, L. Rajsiglova, T. Hudcovic, R. Stepankova, H. Kozakova, J. Dvorak, P. Vodicka, P. Makovicky, M. Levy, P. Rossmann, P. Sima (Prague; Vestec, Czech Republic) (15')
247. Nanoconstructs for targeting the tumor microenvironment. **L. Vannucci**, L. Rajsiglová, D. Stakheev, P. Ceci, E. Falvo, M. Babic, U. Kostiv, F. Caja, J. Krizan, J. Vrba, J. Vrba Jr, D. Vrba, L. Farina, V. Lopresto, G. Ruvio (Prague, Czech Republic; Rome, Italy; Galway, Ireland) (15')
177. Bone marrow microenvironment control of acute lymphoblastic leukemia quiescence and chemotherapy resistance through modulation of bcl6. W. Slone, B. Moses, D. Piktel, R. Evans, I. Hare, K. Martin, K. Brundage, M. Craig, **L.F. Gibson** (Morgantown, WV, USA) (30')
192. Modelisation of the procoagulant activity of cancer cells and their interactions with the microenvironment. **G.T. Gerotziafas**, A. Rousseau, P. van Dreden, E. Mbemba, A. Khaterchi, A.K. Larsen, I. Elalamy (Gennevilliers, France) (30')

## MOLECULAR ONCOLOGY

Room B, 09:00-11:00  
Friday, October 7

Chair Persons: B. Kong, W. Zhang, Q. Yang

240. Histological and molecular analysis of endometrial serous carcinoma. L. Wei, L. Jia, N. Chen, X. Zhang, W. Zheng, **B. Kong** (Jinan, P.R. China; Dallas, TX, USA) (20')
238. Extraperitoneal laparoscopic para-aortic lymphadenectomy in patients with cervical cancer. **W. Zhang** (Wuhan, P.R. China) (20')
236. The anticancer effect of Huaier and its clinical value. **Q. Yang**, X. Song, X. Wang (Jinan, P.R. China) (20')
237. Histological, molecular and clinical analysis of the two subtypes of atypical leiomyoma. **Q. Zhang**, J. Ubago, K. Olmstead Poropatich, R. Dong, J.-J. Wei, B. Kong (Jinan, P.R. China; Chicago, IL, USA) (20')
239. Evaluation of several screening approaches for detection of cervical neoplasia in rural Shandong, China. L.-J. Zong, **Y.-Z. Zhang**, X.-S. Yang, J. Jiang, B.-X. Cui, Y.-B. Qiao, L. Li, K. Jiang, W.-J. Zhang, B.-H. Kong, K. Shen (Ji'nan; Beijing, P.R. China) (20')
241. Sciatic endometriosis induces mechanical hypersensitivity, segmental nerve damage, and robust local inflammation in rats. S. Chen, W. Xie, J.A. Strong, J. Jiang, **J. Zhang** (Jinan, P.R. China; Cincinnati, OH, USA) (20')

## MOLECULAR ONCOLOGY

Room B, 11:30-13:10  
Friday, October 7

Chair Persons: T. Liu, G. Carruba

103. The interplay between histone H3 lysine 4 methyltransferases and N-Myc. **T. Liu** (Sydney, Australia) (25')
357. Merlin/NF2 is associated with elevated aromatase expression and estrogen formation in human liver tissues and liver cancer cells: An unifying model for hepatocellular carcinoma development and progression. L. Cocciadiferro, V. Miceli, O.M. Granata, **G. Carruba** (Palermo, Italy) (25')
180. The complex liaison between vulnerability to cachexia and tumor burden. **A. De Lerma Barbaro** (Busto Arsizio, Italy) (20')
207. Hedgehog signaling in pulmonary fibrosis. B. Hu, J. Liu, Z. Wu, T. Liu, M.R. Ullenbruch, **S.H. Phan** (Ann Arbor, MI, USA) (15')
249. Gammaherpesvirus-mediated deregulation of cellular kinase signaling in cancer. **S. Banerjee**, J. Lu, Q. Cai, Z. Sun, H.C. Jha, E.S. Robertson (Philadelphia, PA, USA; Shanghai, P.R. China) (15')

## GYNECOLOGICAL CANCER/THERAPEUTICS

Room B, 16:00-17:30  
Friday, October 7

Chair Persons: S. Sifakis, N.P. Anagnou

383. Multiomics approaches for gynecological cancer: Insights into novel mechanisms of cervical cancer. **K.J. Pappa**, N.P. Anagnou (Athens, Greece) (20')
322. Altered placental expression of PAPP, PAPP-2 and PLAC-1 in pregnancies with fetal growth restriction. **S. Sifakis**, V. Androutopoulos, A. Pontikaki, N. Papantoniou, D.A. Spandidos (Heraklion; Athens, Greece) (20')
234. Negative conversion of PAX1 methylation after treatment of cervical intraepithelial neoplasia and cervical cancer. **T.-C. Chang**, C.-F. Chang, J.-T. Qiu, M.-Y. Chen, C.-P. Hung, C.-Y. Wen, C.-C. Wu, M.-R. Fong, C.-H. Lai (Taoyuan; New Taipei City, Taiwan, R.O.C.) (15')
262. Significance of molecular markers in ovarian carcinoma: Implications for prognosis and disease progression. **R. Vaclavikova**, K. Elsnerova, B. Mohelnikova-Duchonova, M. Ehrlichova, L. Rob, P. Skapa, M. Hrudka, A. Bartakova, J. Bouda, P. Vodicka, L. Vodickova, P. Soucek (Prague; Pilsen; Olomouc, Czech Republic) (15')
321. DNA methylation in the human placenta and fetal growth. **O. Koukoura**, S. Sifakis, D.A. Spandidos (Larissa; Heraklion, Greece) (10')
323. Endometriosis and breast cancer: A review of the epidemiological studies. **A. Pontikaki**, S. Sifakis, D.A. Spandidos (Heraklion, Greece) (10')

## MOLECULAR ONCOLOGY/microRNAs

Room B, 18:00-19:30  
Friday, October 7

Chair Persons: A. Zaravinos, G. Glady

111. Next-generation sequencing approaches highlight the genetic events that drive B-cell lymphomagenesis. **A. Zaravinos**, L. Chen, Z. Zi, M. Dose, R. Caridha, W. Ren, R. Casellas, Q. Pan-Hammarström (Stockholm, Sweden; Nicosia, Cyprus; Shenzhen, P.R. China; Bethesda, MD, USA) (15')
147. Is it possible to slow down cancer progression by the way of EBV neutralization? **G. Glady** (Colmar, France) (15')
122. miRpower: A web tool to validate survival-associated miRNAs utilizing expression data from 2,060 breast cancer patients. **B. Györfy**, A. Lánckzy, Á. Nagy, G. Bottai, G. Mukácsy, L. Paladini, L. Santarpi (Budapest, Hungary; Milan, Italy) (15')
161. Identification and functional characterization of microRNAs reveal their potential role in the progression of gastric cancer. **C. Li**, G. Liang, W. Yao, J. Sui, X. Shen, Y. Zhang, H. Peng, W. Hong, Y. Ye, Z. Zhang, W. Zhang, L. Yin, Y. Pu (Nanjing; Gansu, P.R. China) (15')
380. Deregulated microRNAs in peripheral blood of lung cancer patients. M. Krutakova, M. Sarlinova, R. Iliev, O. Slaby, T. Matakova, L. Plank, **E. Halasova** (Martin, Slovak Republic; Brno, Czech Republic) (15')
392. Retrogress of the oncogenicity of the IGF signaling pathway by dint of microRNAs in hepatocellular carcinoma. **H.M. El Tayebi** (Cairo, Egypt) (15')

## ENVIRONMENTAL DISEASES/MOLECULAR MEDICINE

Room C, 09:00-11:00  
Friday, October 7

Chair Persons: C. Fenga, V. Rapisarda, M. Libra

372. Oxidative stress evaluation in benzene exposed workers. **C. Fenga**, S. Gangemia, A. Marconi, V. Rapisarda, C. Costa (Messina; Catania, Italy) (25')
369. Fibulin-3 overexpression is associated with asbestos-like fiber exposure. **V. Rapisarda**, R. Salemi, S. Candido, A. Marconi, C. Loreto, V. Cardile, M. Libra, C. Fenga (Catania; Messina, Italy) (20')
370. Role of Neutrophil gelatinase-associated lipocalin (NGAL) in transitional cell carcinoma of the bladder. **S. Candido**, L. Falzone, R. Salemi, J. Polesel, J. McCubrey, M. Libra (Catania, Italy; Greenville, NC, USA) (15')
182. Maize polyamine oxidase in presence of spermine induces cytotoxicity in wild-type and multidrug resistant cancer cells. **S. Ohkubo**, P. Tavladoraki, R. Mancinelli, A. Cona, R. Angelini, E. Gaudio, E. Agostinelli (Rome, Italy) (15')
388. Rehye study: The effect of resveratrol on HYPertension. A. Chrysikou, D. Prodromou, A. Aristotelous, C. Konstantinou, A. Mouzouridou, K. Fokianos, **M. Theodotou** (Limassol; Nicosia, Cyprus) (15')
410. MRI- and EPR-based imaging biomarkers to guide treatment in tumor-bearing mice. **M.K. Cherukuri** (Bethesda, MD, USA) (30')

## MOLECULAR ONCOLOGY

Room C, 11:30-13:00  
Friday, October 7

Chair Persons: N. Telang, A. Jamil, Y. Suzuki-Karasaki

121. Growth inhibitory herbal extracts alter estradiol metabolism in a model for Luminal A molecular subtype of clinical breast cancer. **N. Telang** (Montvale, NJ, USA) (20')
167. Protective effects of ibuprofen on the expression levels of neuronal pentraxins and inflammation in an AlCl<sub>3</sub>-induced mouse model of neurotoxicity. **A. Jamil**, A. Mehboob, T. Ahmed (Islamabad, Pakistan) (20')
282. Tumor-targeting killing of multidrug-resistant human aggressive cancer cells by plasma-activated media via mitochondrial and endoplasmic reticulum damages. **Y. Suzuki-Karasaki** (Tokyo, Japan) (20')
184. Understanding molecular mechanisms with high-throughput analysis and data mining. **C. Sicularli** (Ankara, Turkey) (15')
292. Characterization of lymphomatous lymph nodes before and after chemotherapy using contrast-enhanced ultrasound: A potential imaging modality in detecting lymphoma. **X. Ma** (Chengdu, P.R. China) (15')

## BREAST CANCER

Room C, 16:00-17:30  
Friday, October 7

Chair Persons: Y.A. Luqmani, D.K. Dube

328. Influence of estrogen receptor silencing on miRnome of breast cancer cell lines. **Y.A. Luqmani**, A. Al Ateyah (Safat, Kuwait) (30')
288. Tropomyosin expression and stress fiber formation in malignant and normal human breast epithelial cell lines. **D.K. Dube**, S. Dube, L. Abbott, B.J. Poiesz (Syracuse, NY, USA) (20')
169. Transgenerational effects of ER $\alpha$ 36 overexpression on mammary gland development and molecular phenotype: Clinical perspective for breast cancer risk and therapy. **C. Chamard-Jovenin**, A. Chesnel, E. Bresso, C. Morel, C. Thiébaud, M. Smail-Tabbone, E.-H. Djermoune, M.-D. Devignes, T. Boukhobza, H. Dumond (Vandœuvre-lès-Nancy; Villers les Nancy, France) (20')
170. From ER $\alpha$ 66 to ER $\alpha$ 36: A new predictive marker for cancer progression and therapeutic response in breast tumors? **C. Thiébaud**, C. Morel, A. Harlé, A. Chesnel, A. Leroux, C. Chamard-Jovenin, T. Boukhobza, J.-L. Merlin, H. Dumond (Vandœuvre lès Nancy; Nancy, France) (20')

## MOLECULAR ONCOLOGY/LUNG CANCER

Room C, 18:00-19:30  
Friday, October 7

Chair Persons: D.P. Vageli, S.-C. Bae

307. *In vitro* and *in vivo* models for gastroduodenal reflux-induced nuclear factor- $\kappa$ B activation and its role in laryngopharyngeal carcinogenesis. **D.P. Vageli**, C.T. Sasaki (New Haven, CT, USA) (25')
223. Development of multiple types of lung adenocarcinomas by the inactivation of Runx3 and activation of K-Ras. Y.-S. Lee, **S.-C. Bae** (Cheongju, Republic of Korea) (20')
151. Genomic analysis of the specific tumor biomarkers of non-small cell lung cancer by combining long non-coding RNA and mRNA expression profiling. **Q. Chen**, J. Chen, X. Si, W. Mao, X. Zhang, C. Jiang, W. He, W. Zhang, X. Qiao, J. Lu (Xianyang, P.R. China) (15')
256. The roles of extracellular vesicles in lung cancer. **W.-L. Huang**, C.-C. Lin, S.-R. Wu, W.-C. Su (Tainan, Taiwan, R.O.C.) (15')
332. EGFR gene mutations and ALK rearrangements in lung carcinomas. **M.K. Shin**, J.W. Kim, M.E. Hong (Seoul, South Korea) (15')

## HEMATOLOGICAL MALIGNANCIES/MOLECULAR ONCOLOGY

Room D, 09:00-11:00  
Friday, October 7

Chair Persons: A. Caruso, A. Dimitrakopoulou-Strauss

318. Role of HIV matrix protein p17 variants in lymphoma pathogenesis. **A. Caruso** (Brescia, Italy) (30')
274. PET-CT studies in patients with multiple myeloma for diagnosis and therapy monitoring. **A. Dimitrakopoulou-Strauss** (Heidelberg, Germany) (30')
286. Functional role of the immune receptor Tim-3 in acute myeloid leukaemia cells. **E. Fasler-Kan**, S.M. Berger, V.V. Sumbayev, B.F. Gibbs, I.G. Silva, L. Ruegg, L. Varani (Bern; Bellinzona, Switzerland; Kent, UK) (30')
243. The link between drug resistance in Multiple Myeloma and Hypoxia. **N. Aouali**, M. Bosseler, V. Marani, G. Berchem, B. Janji (Luxembourg City, Luxembourg) (30')

## HEMATOLOGICAL MALIGNANCIES

Room D, 11:30-13:00  
Friday, October 7

Chair Persons: V.V. Sumbayev, F. Timeus

287. Pathobiochemical pathways associated with malignant transformation of human white blood cells and their role in leukaemia progression. **V.V. Sumbayev**, Y.A. Ushkaryov, E. Fasler-Kan, B.F. Gibbs, I.G. Silva, I. Yasinska, L. Varani (Kent, UK; Bern; Bellinzona, Switzerland) (25')
242. PNH clones in paediatric acquired aplastic anaemia and acute lymphoblastic leukaemia. **F. Timeus**, N. Crescenzo, L. Foglia, M.G. Stillitano, C. Dufour, P. Farruggia, E. Barisone, P. Saracco, F. Fagioli (Turin; Genoa; Palermo, Italy) (25')
165. Galectin 3 role in the leukemia microenvironment. **P.P. Ruvolo** (Houston, TX, USA) (20')
402. Telomere length in peripheral blood leukocytes is associated with aggressive prostate cancer. **J. Gu**, Y. He, M. Huang, J. Kim, X. Wu (Houston, TX, USA) (20')



## COLON CANCER

Room D, 16:00-17:30  
Friday, October 7

Chair Persons: S. Savas, S. Adachi

127. Genetic variations and the risk of outcome in colorectal cancer. **S. Savas** (St. John's, Canada) (25')
126. Ultraviolet-C enhances cisplatin-induced downregulation of receptor tyrosine kinases in human colon cancer. **S. Adachi**, K. Saito, J. Kawaguchi, I. Yasuda, M. Shimizu (Gifu, Japan) (20')
244. Prognostic significance of the presence of circulating non-organ-specific autoantibodies in a cohort of cancer patients: A five-year follow-up study. **S. Mancini**, F. Mariani, P. Sena, P. Muratori, L. Muratori, C. Degli Esposti, L. Roncucci (Modena; Bologna, Italy) (15')
277. FoxQ1 enhances tumorigenicity in colorectal cancer through manipulating angiogenic factor and modifying tumor microenvironment. **H. Tang**, J. Zheng, Q. Guo (Kunming, P.R. China) (15')
289. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. **H. Cheng**, C. Liu, G. Luo, Y. Lu, X. Yu (Shanghai, P.R. China) (15')

## GASTROINTESTINAL/HEPATOCELLULAR

Room D, 18:00-19:30  
Friday, October 7

Chair Persons: M.S. Bronze, P. Reichl

171. Global impact of hepatitis C virus: Implications on the pathogenesis of hepatocellular carcinoma. **M.S. Bronze**, N. Ali, C. Houchen (Oklahoma City, OK, USA) (20')
336. Soluble Axl as a biomarker for very early hepatocellular carcinoma. **P. Reichl**, W. Mikulits (Vienna, Austria) (20')
331. The role of KLF4 in colon cancer stem cells. **Z. Leng**, G. Zhang, T. Zhou, J. Li, J. Li (Nanchong, P.R. China) (20')
384. Immune-modulating effect of the cetuximab-based chemoimmunotherapy in patients with colorectal cancer. **L. Holubec**, J. Polivka, V. Liska, M. Safanda (Pilsen; Prague, Czech Republic) (15')
385. The importance of early tumor shrinkage (ETS) and deepness of response (DPR) in assessing the efficacy and prognosis of systemic anticancer treatment. **L. Holubec**, V. Liska, M. Safanda (Pilsen; Prague, Czech Republic) (15')

## THERAPEUTICS/MOLECULAR MEDICINE

Room A, 09:00-11:00  
Saturday, October 8

Chair Persons: H. Modjtahedi, D.E. Gomez, R. Gambari

163. Targeting of HER family members in ovarian cancer. S. Puvanenthiran, S. Essapen, A.M. Seddon, **H. Modjtahedi** (Kingston; Guildford, UK) (30')
327. Telomeropathies: A constellation of related genetic diseases caused by defects in the telomere maintenance machinery. R. Armando, D.M. Gomez, **D.E. Gomez** (Buenos Aires, Argentina) (30')
364. The genotype selection in thalassemia: From the basic genetic defect to HbF associated polymorphisms. **R. Gambari** (Ferrara, Italy) (30')
397. New insights on the regulatory roles of early growth response-1 in the reparative response to vascular injury. **L.M. Khachigian** (Sydney, Australia) (30')

## BREAST CANCER

Room A, 11:30-13:00  
Saturday, October 8

Chair Persons: H. Kuerer, P. Papageorgis

104. Clinical trials for eliminating breast cancer surgery in exceptional responders. **H. Kuerer**, R. van la Parra, G. Rauch, S. Krishnamurthy, A. Caudle, S. DeSnyder, D. Black, A. Lucci Jr, F. Goravanchi, B. Hobbs, R. Hwang, B. Adrada, B. Smith, R. Candelaria, E. Arribas, T. Moseley, G. Babiera, L. Santiago, V. Valero, W. Yang (Houston, TX, USA) (30')
130. Deciphering the molecular complexity of breast cancer metastasis. **P. Papageorgis**, S. Ozturk, A.W. Lambert, C.M. Neophytou, A. Tzatsos, C.K. Wong, S. Thiagalingam, A. Constantinou (Nicosia, Cyprus; Boston, MA; Washington, DC, USA) (30')
105. FAK Tyrosine 407 organizes with integrin  $\alpha V\beta 5$  in advanced triple-negative breast cancer. I. Payan, S. McDonnell, H.M. Torres, W.F.A. Steelant, **S. van Slambrouck** (Brookings, SD; Miami Gardens, FL; Youngstown, OH, USA; Dublin, Ireland) (30')

## EXPERIMENTAL THERAPEUTICS

Room A, 16:00-17:30  
Saturday, October 8

Chair Persons: A.N. Stephens, F. Goravanchi, L.M. Khachigian

254. Dipeptidyl Peptidase 4 – A novel target for ovarian cancer therapy. L.R. Moffitt, A. Wilson, M. Bilandzic, M. Plebanski, M.G. Gorrell, **A.N. Stephens** (Clayton; Melbourne; Sydney, Australia) (30')
154. Reduction of stress and effect of stress on patients having breast oncologic surgery. **F. Goravanchi** (Houston, TX, USA) (30')
382. Enzymes and transporters in the estrogen activation pathways as targets for ovarian cancer therapy. **T. Thalhammer** (Vienna, Austria) (30')

## TUMOR BIOLOGY/MOLECULAR ONCOLOGY

Room A, 18:00-19:30  
Saturday, October 8

Chair Persons: A.K. Larsen, C. Demonacos, M. Krstic-Demonacos

257. Vascular mimicry (VM) in colorectal cancer: Molecular mechanisms, functional characterization and therapeutic implications. **A.K. Larsen**, S. Thouroude, P. van Dreden, G. Gerotziafas, M. Sabbah (Paris; Gennevilliers, France) (30')
265. Reactive Oxygen Species (ROS) and antigen presentation in breast cancer cells. S. Kunchai, K. Satia, M. Krstic-Demonacos, **C. Demonacos** (Manchester; London; Salford, UK) (30')
266. The role of the microenvironment in acute lymphoblastic leukaemia drug response. M. Qattan, E. Bakker, R. Rajendran, D.W.-C. Chen, V. Saha, J. Liu, L. Zeef, J.-M. Schwartz, L. Mutti, C. Demonacos, **M. Krstic-Demonacos** (Manchester; Salford, UK; Kuala Lumpur, Malaysia; Kolkata, India) (30')

## PROSTATE CANCER

Room B, 09:00-11:00  
Saturday, October 8

Chair Persons: S. Abdulkadir, P.M. Ghosh, G. Perletti

334. Selective pressure of anti-androgens on castration resistant prostate cancer. T.M. Steele, M.K. Jathal, **P.M. Ghosh** (Sacramento, CA, USA) (30')
110. Therapeutic targeting of MYC-driven prostate cancer by PIM kinase inhibition. **S. Abdulkadir** (Chicago, IL, USA) (30')
156. The multiparametric magnetic resonance imaging characteristics of the normal, benign and malignant conditions in the prostate. P.J.L. De Visschere, A. Vral, E. Pattyn, M. Praet, **G. Perletti**, V. Magri, G.M. Villeirs (Ghent, Belgium; Milano, Italy) (15')
193. Proinflammatory S100A8/A9 in amyloid formation in the aging prostate: Risk factor for cancer. **L. Morozova-Roche** (Umeå, Sweden) (15')
409. Targeting of WRN helicase by EGS/RNase P and replication stress in cancer cells. N. Orlovetskie, R. Serruya, G. Abboud-Jarrous, **N. Jarrous** (Jerusalem, Israel) (30')

## INFLAMMATION/MOLECULAR ONCOLOGY

Room B, 11:30-13:10  
Saturday, October 8

Chair Persons: M. De Rosa, R. Tabola, D. Basudhar

378. LiCl inhibits cell growth of spheroid colon cancer cell cultures expressing CD133 and CD44v6 markers at the membrane level. V. Costabile, M. Turano, F. Duraturo, P. Delrio, D. Rega, U. Pace, D. Scala, P. Izzo, **M. De Rosa** (Naples, Italy) (25')
264. Postponed esophageal anastomosis-granulation phase of wound healing and a leak incidence. **R. Tabola**, K. Augoff, A. Lewandowski, P. Ziolkowski, P. Szelachowski, K. Grabowski (Wroclaw, Poland) (25')
408. Regulatory effects of NOS2-COX2 in breast cancer progression in tumor microenvironment. **D. Basudhar**, V. Somasundaram, S. Glynn, L.A. Ridnour, R.Y. Cheng, D.A. Wink (Frederick, MD, USA; Galway, Ireland) (20')
379. Isolation and molecular characterization of primary epithelial-mesenchymal colon cancer cell cultures. **V. Costabile**, M. Turano, F. Duraturo, P. Delrio, D. Rega, U. Pace, D. Scala, P. Izzo, M. De Rosa (Naples, Italy) (15')
308. Tumor Necrosis Factor-alpha blockers-induced transcriptional reduction of pro-inflammatory interleukin-33, Toll-like receptors 2 and 9 in psoriatic plaques. **P.G. Doukas**, S.G. Doukas, D.P. Vageli (Kosice, Slovakia; New Haven, CT, USA) (15')

## TUMOR BIOLOGY/CARCINOGENESIS

Room B, 16:00-17:30  
Saturday, October 8

Chair Persons: T. Yamazawa, A. Semczuk

280. Observation of salivary organs in open aqueous solution by atmospheric scanning electron microscopy (ASEM). **T. Yamazawa** (Tokyo, Japan) (25')
390. *TP53* alterations and p53 expression in borderline ovarian tumors (BOTs) in humans. **A. Semczuk**, A. Mrozek, A. Semczuk-Sikora, K. Gałczyński, D. Lewkowicz, Ł. Nowakowski, K. Postawski (Lublin; Rzeszow, Poland) (25')
263. Phenotypic heterogeneity of gastric tissue and intratumoral variation of mRNA level. **A. Babenko**, S. Smirnov, M. Revtovich, R. Smolyakova, A. Shmak (Minsk, Belarus) (20')
330. Vitamin D and cancer. **I. Kostoglou-Athanassiou**, P. Athanassiou (Athens; Thessaloniki, Greece) (20')

## BREAST CANCER

Room B, 18:00-19:30  
Saturday, October 8

Chair Persons: A.A. Alaiya, H.M. Romanska, S. Linardopoulos

138. Objective definition of HER2 status in breast cancer patients by expression proteomics: The path of personalized medicine. **A.A. Alaiya**, Z. Shinwari, T. Twegieri (Riyadh, Saudi Arabia) (15')
159. Diverse role of tetraspanin CD151 in breast cancer progression: Implications for disease prognostication. **H.M. Romanska**, R. Sadej, P. Potemski, R. Kordek (Lodz; Gdansk, Poland) (15')
394. Oxidative phosphorylation genes in breast cancer cells. **L. Grzybowska-Szatkowska**, J. Rzymowska, B. Ślaska (Lublin, Poland) (15')
403. MPS1 inhibition in breast cancer. **S. Linardopoulos** (London, UK) (15')
185. Lateral differences in Ki-67 in breast cancer. **A.P. Dmitrenko** (Rostov, Russia) (15')
231. Targeting breast cancer metastasis: A bioengineering approach. **V. Gkretsi**, A. Stylianou, T. Stylianopoulos (Nicosia, Cyprus) (15')

## MOLECULAR ONCOLOGY/PHARMACOLOGY

Room C, 09:00-11:00  
Saturday, October 8

Chair Persons: M. Acevedo-Duncan, P. Gál, E. Isogai

131. Use of ACPD and ICA-1 as inhibitors of atypical protein kinase C- zeta ( $\zeta$ ) and iota ( $\iota$ ) in metastasized melanoma cells. W.S. Ratnayake, **M. Acevedo-Duncan** (Tampa, FL, USA) (30')
278. Different promoting effect of galectin-1 and -3 on the healing of skin incision and excision: New perspective on wound-type specific therapy. **P. Gál**, T. Vasilenko, I. Kováč, B. Dvořánková, P. Szabo, S. André, H. Kaltner, H.-J. Gabius, K. Smetana Jr. (Košice, Slovak Republic; Prague, Czech Republic; Munich, Germany) (20')
175. Effective activity of synthetic antimicrobial peptides to antibiotic resistant *Staphylococcus aureus*. **E. Isogai**, N. Miyoshi, I. Morozumi, K. Kuroda, K. Ihara, M. Narita, H. Isogai, K. Hiramatsu, T. Sasaki (Sendai; Sapporo; Tokyo, Japan) (20')
172. Mitochondrial function and morphology in platinum-resistant cells. **S. Isonishi**, S. Yanagida, H. Kuroda, K. Morimoto, R. Saitou, Y. Kasahara (Tokyo, Japan) (20')
259. Nanosensors in cancer therapeutics delivery and monitoring. E. Neuhöferová, R. Křivohlavá, M. Kinderman, S. Lukowski, V. Petráková, M. Nesládek, **V. Benson** (Prague; Kladno, Czech Republic; Diepenbeek, Belgium) (15')
316. Docetaxel-loaded lipid microbubbles combined with ultrasound-triggered microbubble destruction (UTMD) for targeted tumor therapy in MHCC-H cells. **Y. Zhang**, R. Chang, M. Li, K. Zhao, H. Zheng, X. Zhou (Xi'an; Luoyang, P.R. China) (15')

## CLINICAL ONCOLOGY/SURGICAL ONCOLOGY

Room C, 11:30-13:00  
Saturday, October 8

Chair Persons: Z. Wang, A.S. Caudle

178. The use of bilateral transcutaneous electroacupuncture for over dilation of gastric tube after esophagectomy. **Z. Wang**, J. Liu, Q. Wu, Q. Wu, C. Dang (Xi'an, P.R. China) (25')
166. Targeted Axillary Dissection: Is it for every patient? **A.S. Caudle**, W.T. Yang, F. Goravanchi, S. Krishnamurthy, H.M. Kuerer (Houston TX, USA) (25')
162. Hyperthermia induces the apoptosis of esophageal squamous cell carcinoma cells through the nuclear translocation of Nrf2. **Y. Yang**, Y. Wang, X. Zuo, H. Yang, Y. Gu, D. Yang (Zhengzhou, P.R. China) (20')
201. Clinical consideration in the management of metastatic gastric cancer. **S. Zhang**, Y. Meng, H. Wang, F. Gao (Jinan, P.R. China) (20')

## 2ND WORKSHOP ON PAEDIATRIC VIROLOGY

Room C, 16:00-17:30  
Saturday, October 8

Chair Persons: M. Theodoridou, A. Kramvis

338. The Greek experience of HIV-1 infection in children. **M. Theodoridou** (Athens, Greece) (25')
339. Hepatitis B vaccination in Africa: Current situation and future challenges. **A. Kramvis** (Johannesburg, South Africa) (25')
340. Zika Virus in pregnancy and infancy - What do the paediatricians need to know? **P. Thiagarajan** (Isle of Man, British Isles) (20')
341. Otolaryngologist's surgical approaches of complicated paediatric viral infections. **G. Kostagianni** (Elefsina, Greece) (10')
342. The educational challenge of Paediatric Virology. **I.N. Mammias**, M. Theodoridou, G. Sourvinos, D.A. Spandidos (Heraklion; Athens, Greece) (10')

## 2ND WORKSHOP ON PAEDIATRIC VIROLOGY

Room C, 18:00-19:30  
Saturday, October 8

Chair Persons: S. Gardner, G. Papaioannou

343. It's never just a virus - Experiences from the frontline. **S. Gardner** (Ormskirk, UK) (25')
344. Multimodality imaging of viral infections in children: CNS and beyond. **G. Papaioannou** (Athens, Greece) (25')
345. Influenza in childhood: A usual suspect. **A. Melidou** (Thessaloniki, Greece) (20')
346. Neurologic manifestations of Influenza A infection (H1N1 pandemic strain) in paediatrics. **M. Koutsaki**, A. Dinopoulos (Athens, Greece) (10')
347. Paediatric viral conjunctivitis - Diagnosis and treatment. **V. Achtsidis**, E. Kozanidou (Athens; Piraeus, Greece) (10')

## BRAIN TUMORS

Room D, 09:00-11:00  
Saturday, October 8

Chair Persons: W. Lin, F. Lefranc

183. Dual role of the integrated stress response in medulloblastoma tumorigenesis. **W. Lin** (Minneapolis, MN, USA) (25')
153. The glioblastoma (GBM) journey. **F. Lefranc** (Brussels, Belgium) (25')
284. Proteoglycans of brain extracellular matrix as potential molecular targets of dexamethasone side-effects during anti-glioma therapy. A.Y. Tsidulko, G.M. Kazanskaya, D.V. Kostromskaya, R.S. Kiselev, A.M. Volkov, A.S. Gaitan, A.L. Krivoschapkin, G. De la Bourdonnaye, **S.V. Aidagulova**, E.V. Grigorieva (Novosibirsk; Toulouse, France) (25')
386. Therapeutic implications of mTOR inhibitors in genetically heterogeneous glioblastoma. E. Solli, A. Wang, A. Amin, J. Feldman, A. Braun, R. Murali, **M. Jhanwar-Uniyal** (Valhalla, NY, USA) (15')
135. The role of Notch signal pathway and its antagonist in the pathogenesis of non-functioning pituitary adenomas. **J. Zhang**, H. Gao, Y. Zhang (Beijing; Huancui, P.R. China) (15')
214. Role of the hypoxia-inducible factors (HIF1, HIF2) in glioblastoma: Focus on erythropoietin (EPO) and beta-III tubulin ( $\beta$ III-t). **M. Bernaudin** (Caen, France) (15')

## BRAIN TUMORS/CLINICAL ONCOLOGY

Room D, 11:30-13:00  
Saturday, October 8

Chair Persons: A.A. Alaiya, I. Groisman

139. Neuroproteomics: Development and validation of protein biomarkers from human cerebral cortex for diagnostic and prognostic management of epilepsy and brain tumor patients. **A.A. Alaiya**, Z. Shinwari, A. Mustafa, S. Baz, H. Aldalaan, I. Al Thubaiti, F. Alotaibi, H. Alhendi, A. Al Semari (Riyadh, Saudi Arabia) (25')
191. CPEB1 restrains proliferation of glioblastoma cells through the regulation of p27Kip1 mRNA translation. S. Galardi, M. Petretich, G. Pinna, S. D'Amico, F. Loreni, A. Michienzi, **I. Groisman**, S.A. Ciafrè (Rome, Italy; Gif-sur-Yvette, France; Heidelberg, Germany) (25')
395. Compliance and safety of lapatinib therapy for the treatment of metastatic breast cancer. **R. Addeo**, L. Montella, A. Prudente, A. Nappi, G. Cennamo, S. Del Prete (Frattamaggiore, Italy) (25')
396. Dichloroacetate: Targeting energy metabolism in immune cells. **M. Sounidaki** (Larisa, Greece) (15')



## MOLECULAR ONCOLOGY/MOLECULAR MEDICINE

Room D, 16:00-17:30  
Saturday, October 8

Chair Persons: S. Chandramathi, E. Rizos

255. Association of intestinal parasitic infection with colorectal cancer: Special focus on *Blastocystis* sp. **S. Chandramathi**, K. Suresh, U.R. Kuppusamy (Kuala Lumpur, Malaysia) (30')
152. Schizophrenia and cancer: An overview of the co-morbidity and the role of microRNAs. **E. Rizos**, N. Sifakas, A. Papanastasiou, E. Skourti, C. Papageorgiou, J. Tsoporis, Th. Parker, D.A. Spandidos, E. Katsantoni, V. Zoumpourlis (Athens; Heraklion, Greece; Toronto, Canada) (20')
212. Discussion on the tumor treatment of traditional chinese medicine: Discover the new therapeutic strategy. **X. Sun**, F. Hu (Shenzhen, P.R. China) (20')
290. Establishing Fascin as a key regulator in oral cancer metastasis. **N. Mohanty**, S. Routray (Bhubaneswar, India) (20')

## MOLECULAR MEDICINE/ONCOLOGY

Room D, 18:00-19:30  
Saturday, October 8

Chair Persons: P. Vodička, L.M. Junie, S. Gurzu

190. Genetic and phenotypic features delineating the treatment efficacy and response to 5-fluorouracil in sporadic colorectal cancer patients. **P. Vodička**, P. Souček, J. Slyšková, A. Čumová, T. Kunická, B. Pardini, A. Naccarati, L. Vodičková, V. Vymetálková, P. Bendová, K. Jirasková, L. Bártů, S. Vodénková, V. Liška, M. Kroupa, D. Sliva, A. Opattová (Prague; Pilsen, Czech Republic; Indianapolis, IN, USA) (20')
229. Enterotoxin genes and antibiotic resistance correlations in *S. aureus*. **L.M. Junie**, L.M. Simon, M. Flonta, A. Almasanu, D. Homorodean, M.L. Vică (Cluj-Napoca, Romania) (20')
108. Epithelial-mesenchymal transition in gastric cancer. **S. Gurzu**, A.M. Fetyko, T. Bara, T. Bara Jr, I. Jung (Tirgu-Mures, Romania) (20')
109. Incidental findings of small cell carcinomas with paraneoplastic neurological syndromes. **I. Jung**, R. Balasa, B. Nagy, S. Gurzu (Tirgu-Mures, Romania) (15')
398. Dynamic cancer microenvironment and cellular plasticity. **G. Calibasi-Kocal** (Izmir, Turkey) (15')

POSTERS (Poster viewing during the entire congress)

112. Transcriptome sequencing analysis of diffuse large B-cell lymphoma. **A. Zaravinos**, L. Chen, Z. Zi, W. Ren, R. Caridha, Q. Pan-Hammarström (Stockholm, Sweden; Nicosia, Cyprus; Shenzhen, P.R. China)
113. Cytochrome P450 4A14, a target for the treatment of renal fibrosis. **Y. Zhou**, S. Li, M. Gao, S. Huang, R. Cao, Y. Guan (Shenzhen, P.R. China)
124. Diagnosis of renal cancer from urine by quantitative methylation-specific PCR (qMSP). **R. Dumache**, D. Ionescu, A.F. Rogobete, R. Minciu (Timisoara, Romania)
150. Bio Immun(G)en Medicine, “BI(G)MED”, or how to use epigenetics as a therapeutic tool in cancer. **G. Glady** (Colmar, France)
164. Immunological link between human and animal caliciviruses revealed by monoclonal antibodies to animal caliciviruses. **V. Sologub**, I. Koromyslova, A. Bychenko, A. Muhin (Moscow, Russia)
168. mpMRI-histopathological correlations of normal, benign and malignant conditions of the prostate. P.J.L. De Visschere, **A. Vral**, G. Perletti, E. Pattyn, M. Praet, V. Magri, G.M. Villeirs (Ghent, Belgium; Varese; Milano, Italy)
173. Complex self-assembly of pyrimido[4,5-d]pyrimidine nucleoside supramolecular structures. **Y. He** (Chengdu, P.R. China)
179. External Qi of Qigong induces apoptosis and inhibits multiple signaling pathways in colorectal cancer cells. X. Yan, H. Shen, H. Jiang, D. Hu, J. Wang, **X. Wu** (Chongqing, P.R. China; New York, NY; Boston, MA, USA)
181. A comparative study of hypo- and conventional fractionated whole breast irradiation. **K.H. Shin**, S.-W. Lee, K. Kim, S.W. Park (Seoul, Republic of Korea)
186. Effect of deep axillary lymphodissection on the survival of patients with breast cancer. **A.P. Dmitrenko** (Rostov, Russia)
187. Role of lymph node status after excisional biopsy in breast cancer. **A.P. Dmitrenko** (Rostov, Russia)
196. H3K4 Tri-methylation is different between different chromatin configurations. L. Qiao, L. Zhang, X. Wu, J. Xin, F. Kong, J. Xie, **Y. Liu** (Fuyang, P.R. China)
200. Testing of new anticancer therapeutics based on low-molecular-weight inhibitors of DNA-PK. **M. Pospíšilová**, M. Seifrtová, M. Andrš, J. Korábečný, M. Řezáčová (Prague; Kralove, Czech Republic)
204. Distinguishing cancer type using Raman spectroscopy. **H. Fujita**, T. Ichimura, T.M. Watanabe (Osaka, Japan)
206. Screening and functional analysis of E3 ubiquitin ligase that regulates Snail-mediated EMT. S.-H. Park, K.-J. Ryu, H.T. Han, H.-J. Kim, S.H. Kim, **J. Yoo** (Jinju, Republic of Korea)
208. Dynamic regulation of ARF expression upon mitogenic stimulation. **J.-W. Lee**, S.-C. Bae (Cheongju, Republic of Korea)
210. Assessment of *Rhodiola kirilowii* supplementation of pregnant and lactating mice on selected angiogenesis parameters in their serum. R. Zdanowski, J. Wilczak, E. Skopińska-Różewska, A. Borecka, **S. Lewicki** (Warsaw, Poland)
211. The therapeutic experiment of HER2-positive recurrent salivary duct carcinoma by molecular gene target drug with irradiation. **H. Maeda**, S. Agena, T. Uehara, S. Matayoshi, Y. Yamashita, H. Hirakawa, M. Suzuki (Okinawa, Japan)
213. FES mediates the crosstalk between Notch and SRC/STAT3 signaling pathway. C.H. Won, Y.M. Choi, **J.H. Lee** (Seoul, Republic of Korea)
215. Erythropoietin: A mediator of hypoxia-induced treatment resistance in brain tumors. E. Pérès, A. Gérard, C. Anfray, K. Bordji, D. Divoux, J. Toutain, **M. Bernaudin**, S. Valable, E. Petit (Caen, France)

216. Hyperoxic gas-induced changes in two models of glioma: An MRI study to assess blood volume and oxygen saturation in rats. A. Chakhoyan, A. Corroyer-Dulmont, M.M. Leblond, A. G rault, J. Toutain, L. Chazavie, D. Divoux, E. Petit, E.T. MacKenzie, F. Kauffmann, N. Delcroix, **M. Bernaudin**, O. Touzani, S. Valable (Caen, France)
217. Hypoxia favors M2 macrophages by inducing macrophage polarization and re-education in glioblastoma. M.M. Leblond, A.N. G rault, A. Corroyer-Dulmont, E. Petit, **M. Bernaudin**, S. Valable (Caen, France)
218. HIF-2 $\alpha$ , but not HIF-1 $\alpha$ , is essential for hypoxic induction of class III  $\beta$ -tubulin expression in human glioblastoma cells. K. Bordji, A. Grandval, M. Sehili, E. Lechapt-Zalcman, **M. Bernaudin** (Caen, France)
219. NF-kappa B activation of p53. A potential mechanism of inducing cell apoptosis in lncRNA MEG3-mediated ER stress. R.-P. Chen, Z.-L. Huang, L.-X. Liu, M.-Q. Xiang, G.-P. Li, J.-L. Feng, B. Liu, **L.-F. Wu** (Shantou, P.R. China)
221. Isoquinoline alkaloid scoulerine affects proliferation and viability of leukemia cells, induces apoptosis and arrests cell cycle. **K. Habartova**, R. Havelek, L. Cahlikova, M. Rezacova (Hradec Kralove, Czech Republic)
222. RUNX3 inactivation and the initiation of lung tumorigenesis. **Y.-S. Lee**, S.-C. Bae (Cheongju, Republic of Korea)
225. Glioblastoma stem cells targeted therapy via regulation of mitochondrial UQCRB function. **N. Jung**, H.J. Kwon, H.J. Jung (Asan-si, Chungnam; Seoul, Republic of Korea)
245. Subclinical inflammation of colorectal mucosa is related to systemic oxidative balance in healthy adult subjects. **S. Mancini**, F. Mariani, P. Sena, M. Benincasa, L. Roncucci (Modena, Italy)
252. Genetic biomarkers of prognosis of gynecological carcinomas. **K. Elsnerova**, B. Mohelnikova-Duchonova, M. Ehrlichova, I. Gut, A. Bartakova, L. Rob, P. Skapa, M. Hruda, J. Bouda, P. Vodicka, P. Soucek, R. Vaclavikova (Prague; Pilsen; Olomouc, Czech Republic)
260. New approaches in studying the breast cancer microenvironment. R. Křivohlavá, E. Neuhöferová, M. Kinderman, **V. Benson** (Prague, Czech Republic)
268. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP binding partners TEAD4 and RUNX3. **J.-W. Jang**, M.-K. Kim, S.-C. Bae (Cheongju, Republic of Korea)
273. Novel zinc phthalocyanine as a promising photosensitizer for photodynamic therapy of oesophageal cancer. W. Kuzyniak, J. Berkholz, B. Hoffmann, B. Nitzsche, G. Steinemann, J. Schmidt, K. Tafreshian, E. Ermilov, **M. Höpfner** (Berlin, Germany)
279. Differences in the treatment of skin incision and excision: from physical to pharmacological approach. **T. Vasilenko**, M. Novotný, I. Kováč, K. Jakubčová, M. Hollý, M. Slezák, A. Vrzgula, P. Gál (Košice, Slovak Republic)
283. Animacroxam - A novel compound for the treatment of testicular germ cell cancer. G. Steinemann, W. Kuzyniak, B. Nitzsche, B. Hoffmann, A.R. Pries, **M. Höpfner** (Berlin, Germany)
285. The role of heparansulfate degradation in adenomyosis. **S.V. Aidagulova**, D.A. Solyanikov, Y.S. Timofeeva, I.O. Marinkin (Novosibirsk, Russia)
291. Pharmacological activation of estrogen receptor- $\alpha$  and - $\beta$  differentially modulates open and sutured wound healing in a rat model. **M. Novotný**, T. Vasilenko, I. Kováč, B. Dvořánková, P. Szabo, K. Smetana Jr, P. Gál (Prague, Czech Republic)
294. *Atropa belladonna* L. and *Plantago lanceolata* L. water extracts: Comparison of wound healing activities. **I. Kováč**, T. Vasilenko, B. Dvořánková, P. Szabo, K. Jakubčová, J. Belák, H.-J. Gabius, K. Smetana Jr, P. Gál (Košice, Slovak Republic; Prague, Czech Republic; Munich, Germany)
296. Adenosine induces apoptosis and autophagy via ER stress in human hepatoma cells. X.-T. Zhou, Z.-J. Pu, L.-X. Liu, R.-P. Chen, M.-Q. Xiang, G.-P. Li, J.-L. Feng, B. Liu, **L.-F. Wu** (Shantou, P.R. China)

297. Implication of RhoA, RhoB and RhoC GTPases in Herpes Simplex Virus type-1 (HSV-1) infection. **N. Goulidaki**, D.A. Spandidos, G. Sourvinos (Heraklion, Greece)
299. Increased methylation of tumor suppressor genes p16, MLH1 and MGMT in elderly with high serum folate concentrations. **A.M. Ronco**, H. Sánchez, L. Lera, M.B. Hossain, K. Broberg, S. Hirsch, M. Llanos (Santiago, Chile; Stockholm, Sweden)
301. Sensitivity to the natural and synthetic retinoids in relation to the expression of selected protein markers in neuroblastoma cell lines. P. Chlapek, V. Slavikova, J. Sterba, **R. Veselska** (Brno, Czech Republic)
302. Detailed analysis of phosphorylated receptor tyrosine kinases and downstream signaling pathways in selected pediatric malignancies. J. Neradil, K. Melicharkova, P. Mudry, **R. Veselska**, J. Sterba (Brno, Czech Republic)
303. Stress during lactation reprograms the hepatic endocannabinoid system: Association with development of glucose intolerance and insulin resistance in adult mice. V. Castillo, H. Pasmans, A.M. Ronco, **M. Llanos** (Santiago, Chile)
305. Nuclear localisation of proteoglycans in normal and cancer prostate cells. A.V. Suhovskih, **E.V. Grigorieva** (Novosibirsk, Russia)
313. Renin-angiotensin system in breast cancer-angiotensinogen metabolism in MCF-7, MDA-MB-231 and T47D cell lines. **B. Bujak-Giżycka**, J. Madej, J. Totoń-Żurańska, M. Kołton-Wróz, K. Kuś, R. Korbut (Krakow, Poland)
315. MnTbAP-sensitive ROS-driven pro-survival pathway prevents cancer cells from mitochondrial and endoplasmic reticulum damages. M. Suzuki-Karasaki, M. Suzuki-Karasaki, **Y. Suzuki-Karasaki** (Tokyo, Japan)
317. The apoptotic effect of ultrasound irradiating docetaxel-loaded microbubbles on human liver cancer cells MHCC-H. Y. Zhang, **R. Chang**, M. Li, K. Zhao, H. Zheng, X. Zhou (Xi'an; Baoji; Luoyang, P.R. China)
319. Determining *Neisseria gonorrhoeae* susceptibility to ciprofloxacin in urine samples using PCR techniques. **M.L. Vică**, L.M. Junie, H.V. Matei (Cluj-Napoca, Romania)
320. E2F8 regulates G2/M cell cycle in prostate cancer. J.N. Chun, S. Lee, **J.-H. Jeon** (Seoul, Republic of Korea; Salt Lake, UT, USA)
324. The role of DNA methylation in the pathogenesis of endometriosis. **O. Koukoura**, S. Sifakis, D.A. Spandidos (Larissa; Heraklion, Greece)
325. DNA methylation in ovarian cancer. **O. Koukoura**, A. Daponte, S. Sifakis, D.A. Spandidos (Larissa; Heraklion, Greece)
329. Proliferation and invasion markers expressed at stromal and epithelial cells of ductal carcinomas and corresponding lymph node metastasis. F.S. Pasini, S. Nonogaki, F.A. Soares, M.M. Brentani, A.F. Logullo, **F.G. Lopes Mundim** (Sao Paulo, Brazil)
348. Coxsackie viruses and myocarditis in children. **M. Calachanis** (Athens, Greece)
349. Coxsackie virus A6 and onychomadesis: A case report and literature review. **C. Koutsaftiki** (Athens, Greece)
350. The antivaccination movement: A brief historical overview. **C. Koutsaftiki** (Athens, Greece)
351. Treatment options for Hepatitis C virus in childhood. **A. Kramvis** (Johannesburg, South Africa)
352. Paediatric Virology as new paediatric subspecialty: Challenges, difficulties and limitations. **I.N. Mammas**, M. Theodoridou, G. Sourvinos, D.A. Spandidos (Heraklion; Athens, Greece)
353. Influenza virus activity in children < 18 years old in N. Greece, 2015-2016. M. Christoforidi, **A. Melidou**, G. Gioula, M. Exindari, N. Malisiovas (Thessaloniki, Greece)
354. Novel molecular diagnostic methods for clinical diagnostic virology. **I.N. Mammas**, S.P. Derdas, C. Kokkinaki, I. Tzoraki, G. Sourvinos, D.A. Spandidos (Heraklion, Greece)

355. Molecular detection of human papillomaviruses in childhood: An update. **A. Zaravinos**, I.N. Mamas, G. Sourvinos, D.A. Spandidos (Nicosia, Cyprus; Heraklion, Greece)
359. The  $\Delta\gamma(+25\text{ G}\rightarrow\text{A})$  polymorphism is associated with high HbF production leading to a decrease in binding activity of the LYAR transcription factor to the  $\Delta\gamma$ -globin gene in  $\beta$ -thalassemia patients. G. Breveglieri, L.C. Cosenza, C. Gemmo, M.R. Gamberini, F. Chiavilli, C. Zuccato, M. Pasin, **M. Borgatti**, I. Lampronti, A. Finotti, R. Gambari, N. Bianchi (Ferrara, Italy)
360. The multicenter THALAMOSS cellular Biobank for  $\beta$ -Thalassemia. L.C. Cosenza, L. Breda, G. Breveglieri, C. Zuccato, A. Finotti, I. Lampronti, S. Satta, L. Manunza, F.R. De Martis, P. Moi, S.L. Thein, S. Menzel, A. Breton, C. Lederer, **M. Borgatti**, M. Kleanthous, S. Rivella, R. Gambari, N. Bianchi (Ferrara; Cagliari, Italy; Philadelphia, PA, USA; London, UK; Nicosia, Cyprus)
362. Possible detection of Autologous Blood Transfusion (ABT) based on circulating plasma microRNAs involved in erythroid differentiation and fetal hemoglobin induction. **A. Finotti**, N. Lamberti, J. Gasparello, N. Bianchi, E. Fabbri, L.C. Cosenza, R. Milani, I. Lampronti, F. Dalla Corte, R. Reverberi, F. Manfredini, R. Gambari (Ferrara, Italy)
363. PNAs targeting BCL11A at the miR-210 binding sites down-regulate BCL11A and up-regulate  $\gamma$ -globin mRNA. J. Gasparello, E. Fabbri, N. Bianchi, G. Breveglieri, C. Zuccato, G. Montagner, L.C. Cosenza, I. Lampronti, F. Salvatori, M. Borgatti, A. Romanelli, C. Avitabile, M. Saviano, R. Gambari, **A. Finotti** (Ferrara; Napoli; Bari, Italy)
365. Antitumor effects of new synthetic isoxazole derivatives. I. Lampronti, C. Gemmo, **R. Gambari**, R. Baruchello, D. Simoni (Ferrara, Italy)
366. Anti-inflammatory activity of novel 4,6,4'-trimethylangelicin's analogues: Effects on the NF- $\kappa$ B activity and IL-8 expression in cystic fibrosis IB3-1 cells. I. Lampronti, R. Milani, M.G. Manzione, **R. Gambari**, G. Cabrini, G. Marzaro, A. Chilin (Ferrara; Verona; Padova, Italy)
367. Laser controlled singlet oxygen generation in mitochondria to promote mitochondrial DNA replication *in vitro*. X. Zhou, **Y. Wang**, H. Zhang (Lanzhou, P.R. China)
368. Overexpression of the Transcription Factor Yin Yang 1 in non-Hodgkin lymphoma is associated with chemo-immune resistance. **M. Libra**, S. Candido, L. Falzone, G. Malaponte, B. Bonavida (Catania, Italy; Los Angeles, CA, USA)
376. Alternative splicing and radiobiology. **C. Di**, J. Hoheisel, H. Zhang (Lanzhou, P.R. China; Heidelberg, Germany)
377. Anti-inflammatory activities of *Dictamnus dasycarpus* Turcz. on contact dermatitis in mice. **H. Kim**, M. Kim, H. Kim, G.S. Lee, W.G. An, S.I. Cho (Iksan, Republic of Korea)
381. Association of DPD gene polymorphisms with colorectal cancer in Slovak patients. **T. Matakova**, E. Halasova, A. Dzian, M. Skerenova (Martin, Slovakia)
391. Identification of novel therapeutic targets in the secretome of ionizing radiation-induced senescent tumor cells. **S.H. Jung**, H.J. Hwang, H.C. Lee, H.J. Park, J.-S. Lee (Incheon, Republic of Korea)
393. Expression profiling of CD274 mRNA in breast cancer tissues. M.M. Hamed, L.K. Abdel-Aal, **H.M. El Tayebi** (Cairo, Egypt)
399. TERT-CLPTM1 locus polymorphism (rs401681) is associated with the prognosis of hepatocellular carcinoma. W.-J. Park, Y.-R. Heo, S.-J. Jung, **J.-H. Lee** (Daegu, Republic of Korea)
405. FAK Tyrosine 407 organized with integrin  $\alpha\text{V}\beta\text{5}$  receptor in advanced triple negative breast cancer. **H. Torres**, I. Payan, S. McDonnell, W. Steelant, S. van Slambrouck (Brookings, SD; Miami Gardens, FL; Youngstown, OH, USA; Dublin, Ireland)
406. Anti-cancer activity of Billy goat weed. **F. Acheampong**, J. Reilly, C. Larbie (Brookings, SD, USA; Cambridge, MA, USA; Kumasi, Ghana)
411. Tethering tissue inhibitors of metalloproteinase (TIMP) to the cell surface for enhanced activity against cervical cancer cell (HeLa) progression. **M.H. Lee**, B. Jiang, A. Tsigkou (Suzhou, P.R. China)